Press Release
29 October 2025 10:00:00 CET

MEDIVIR

Medivir postpones the appointment of a new Nomination Committee

Stockholm, Sweden — Medivir AB (the "Company" or "Medivir") (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the Nomination Committee for the 2026 Annual General Meeting will be appointed after the planned rights issue is completed.

The Nomination Committee of Medivir normally consists of the Chairman of the Board and one representative from each of the three largest known shareholders in terms of voting power in the Company as of the last banking day in September prior to the Annual General Meeting.

As the planned rights issue, disclosed on October 8, 2025, may result in significant changes in the ownership structure, the appointment of a new Nomination Committee will take place after the completion of the planned rights issue. The composition of the Nomination Committee is expected to be announced in January 2026.

This represents a deviation from section 2.5 of the Swedish Code of Corporate Governance, which states that the composition of the Nomination Committee should be announced no later than six months before the Annual General Meeting. The Company considers that a deviation is justified in this case as it ensures that the composition of the Nomination Committee reflects the actual ownership structure in the Company ahead of the Annual General Meeting.

For additional information, please contact;
Magnus Christensen
Chief Financial Officer
Medivir AB
M: +46 73 125 06 20
Email: Magnus.Christensen@medivir.com

About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.